Microarray Analysis for Human Genetic Disease
Primary Purpose
Breast Neoplasm, Hereditary Neoplastic Syndrome, Melanoma
Status
Completed
Phase
Locations
International
Study Type
Observational
Intervention
Sponsored by
About this trial
This is an observational trial for Breast Neoplasm focused on measuring Melanoma, Breast Cancer, Gene Expression, DNA Chip Technology, Expressed Sequence Tags
Eligibility Criteria
Clinical inclusion/exclusion criteria will be dependent upon the collaborating Institutions' requirements.
Sites / Locations
- Arizona Cancer Center
- Johns Hopkins University
- University of Michigan
- Memorial Sloan Kettering Cancer Center
- MD Anderson Cancer Center
- Helsinki University Central Hospital
- University of Iceland
- University of Lund
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00001898
First Posted
November 3, 1999
Last Updated
June 30, 2017
Sponsor
National Human Genome Research Institute (NHGRI)
1. Study Identification
Unique Protocol Identification Number
NCT00001898
Brief Title
Microarray Analysis for Human Genetic Disease
Official Title
Microarray Analysis for Human Genetic Disease
Study Type
Observational
2. Study Status
Record Verification Date
May 20, 2008
Overall Recruitment Status
Completed
Study Start Date
June 29, 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
May 20, 2008 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Human Genome Research Institute (NHGRI)
4. Oversight
5. Study Description
Brief Summary
This study will look at genetic changes which occur in the development of male and female breast cancer and other cancer. It will use a new technology called DNA microarray hybridization that looks at a wide array of genes to identify disease-associated patterns in the human genome (complete set of human genes). Numerous studies have linked particular genes to a given disease, but there is very little information on patterns of gene expression (production of proteins from genetic coding) in the entire human genome.
Pinpointing genetic abnormalities in disease may help classify different forms of cancer and perhaps lead to new avenues of treatment or prevention. A primary goal of this study will be to create a database of gene expression for human cancers and other disorders that will provide the basis for finding genetic abnormalities in disease.
Tumors specimens used in this study will be taken from tissues biopsied from patients with breast, colon cancer, sarcomas or melanoma as part of their routine care. Patients in the study will be among those receiving care at the: Department of Oncology, University Hospital, University of Lund, Sweden (breast cancer); Department of Medicine, University of Michigan, Ann Arbor, Michigan (breast cancer); Surgery Branch, National Cancer Institute, Bethesda, Maryland (melanoma), Johns Hopkins Univ. (colon cancer), Memorial Sloan Kettering (sarcoma).
Patients in the study will have a family history taken and will complete a questionnaire. Some patients will be asked to have a blood test. Breast cancer patients will have a mammogram if one has not been done within the last year.
Detailed Description
The purpose of our study is to make use of a novel technology that the Cancer Genetics Branch of the NHGRI has been a leader in developing. This technology for genome-wide expression analysis, DNA microarray hybridization, is the focus of our protocol. We will access tissue banks collected by our collaborators that contain excess tissues obtained during routine clinical care. Specimens will be processed for large-scale gene expression analysis and DNA copy number determination using DNA microarrays. The development and analysis of this gene expression and gene copy number database are the primary purpose of this study. Currently available and new bioinformatics tools will be applied to the data for the characterization of disease subsets (e.g., early vs. advanced stage cancer) as well as to mine the data for specific genes which are linked to given disease states.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasm, Hereditary Neoplastic Syndrome, Melanoma, Ovarian Neoplasm
Keywords
Melanoma, Breast Cancer, Gene Expression, DNA Chip Technology, Expressed Sequence Tags
7. Study Design
Enrollment
1500 (false)
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Clinical inclusion/exclusion criteria will be dependent upon the collaborating Institutions' requirements.
Facility Information:
Facility Name
Arizona Cancer Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109-0624
Country
United States
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4096
Country
United States
Facility Name
Helsinki University Central Hospital
City
Helsinki
Country
Finland
Facility Name
University of Iceland
City
Reykjavik
Country
Iceland
Facility Name
University of Lund
City
Lund
Country
Sweden
12. IPD Sharing Statement
Citations:
PubMed Identifier
9731524
Citation
Ermolaeva O, Rastogi M, Pruitt KD, Schuler GD, Bittner ML, Chen Y, Simon R, Meltzer P, Trent JM, Boguski MS. Data management and analysis for gene expression arrays. Nat Genet. 1998 Sep;20(1):19-23. doi: 10.1038/1670.
Results Reference
background
Learn more about this trial
Microarray Analysis for Human Genetic Disease
We'll reach out to this number within 24 hrs